- Trial Phase
- Phase 2
- Time to Market
- Unknown — MT-601 is in Phase 2 for lymphoma (APOLLO study) and preparing a Phase 1 pancreatic cancer study (expected Q1 2027). A registrational trial has not yet begun. At minimum 3-5 years away from potential approval, if ever.
- Why 4/10
- Next hard catalyst is the initiation of the company-sponsored Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer, expected Q1 2027 (~4-5 months away). However, trial start is a softer catalyst than a data readout or PDUFA, and the stock is a micro-cap ($22M) where near-term survival depends on financing. Score 4 reflects no pending binary regulatory or pivotal readout within ~12 months.
Watch for the Phase 1 pancreatic cancer study initiation in Q1 2027 and the upcoming Q3 2026 earnings (Nov 11). The critical near-term risk is the company's cash runway — with ~$17M at year-end 2025 and a $12M+ annual burn, MRKR likely needs to raise capital within months, which would dilute existing shareholders. The massive analyst price target spread ($5.60-$10 vs $0.96 stock) suggests genuine clinical promise but extreme execution risk at current funding levels.
Price Chart
Executive Summary
MT-601 is Marker Therapeutics' lead pipeline asset — a non-viral, multi-target T cell (MAR-T) therapy being developed for hematologic cancers (non-Hodgkin lymphoma, Hodgkin lymphoma) and solid tumors (pancreatic cancer). Early clinical data from investigator-sponsored studies has shown promising response rates: a 66% objective response rate in relapsed/refractory non-Hodgkin lymphoma (APOLLO study), 78% ORR in Hodgkin lymphoma, and a 84.6% disease control rate in pancreatic cancer when combined with chemotherapy (published in Nature Medicine). In October 2026 the FDA awarded a competitive $2.6M Orphan Products Clinical Trials Grant for a company-sponsored Phase 1 pancreatic cancer study expected to start in Q1 2027. However, Marker Therapeutics (Nasdaq: MRKR, ~$22M market cap) faces significant financial pressure — $17M in cash at year-end 2025 funded operations only through Q4 2026, the stock trades near its 52-week low of $0.84, and a proposed 4.3x increase in authorized shares signals impending dilution. The stock represents a high-risk/high-reward binary bet on early-stage cell therapy data translating into registrational success, with meaningful clinical promise but precarious financing.
How It Works
MT-601 is an investigational cell therapy that trains a patient's own T cells (a type of immune cell) to recognize and kill cancer cells. Unlike CAR-T therapies (which are genetically engineered in a lab), MT-601 is a 'MAR-T' therapy that identifies and multiplies T cells already naturally capable of targeting multiple tumor-associated antigens simultaneously. This multi-targeting approach is designed to reduce the chance that cancers escape the immune response by mutating to lose a single target antigen — a common failure mode for CAR-T. The cells are grown outside the body and then infused back into the patient.
Trial Status
MT-601 has completed enrollment in the APOLLO Phase 2 study in relapsed/refractory non-Hodgkin lymphoma, reporting a 66% objective response rate (8/12 evaluable patients) including 50% complete responses. A prior Baylor investigator-sponsored Phase 1/2 study in pancreatic cancer (published in Nature Medicine) showed an 84.6% disease control rate and 14.1-month median overall survival when combined with chemotherapy. A new company-sponsored Phase 1 study in locally advanced unresectable pancreatic cancer has been awarded a $2.6M FDA Orphan Products Clinical Trials Grant, with enrollment initiation expected in Q1 2027.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings report on November 11, 2026 — cash runway update and clinical progress
- Phase 1 pancreatic cancer study initiation expected Q1 2027 — the next meaningful clinical milestone
- Potential capital raise / financing event given cash runway ending Q4 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Marker Therapeutics, Inc. 8-K MRKR ·Originating report